Clinical Trial Update: Managed Access Programs for VAY736, Ianalumab

View source ↗

Summary

Clinical trial update indicating that managed access programs exist for the investigational antibody ianalumab (VAY736) from Novartis, for primary immune thromb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Sjögren Syndrome

Drugs mentioned

• Ianalumab (VAY736) (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Immune Thrombocytopenia, Sjögren's Syndrome | Status: AVAILABLE